CS43158 / Chipscreen - LARVOL DELTA

Chipscreen Biosciences Announced NMPA Approval of IND for CS43158, an AML Candidate Discovered via the AI-enabled Chemical Genomics Platform (Businesswire) - "CS43158 is a multikinase inhibitor with global patent protection, independently developed by Chipscreen Biosciences leveraging its AI-ChemGen Platform....Preclinical studies indicate that CS43158 has favorable pharmacokinetics and a favorable safety profile, and exhibits superior antitumor activity over reference compound across multiple models. In resistant models of existing therapies, sequential treatment with CS43158 significantly suppresses tumor progression, demonstrating its robust potential to overcome clinical resistance."

New trial • Preclinical • Acute Myelogenous Leukemia